Vaxxinity to Participate at the Bank of America Securities 2022 Healthcare Conference
May 05 2022 - 7:00AM
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the
development of a new class of immunotherapeutic vaccines, today
announced that Mei Mei Hu, President and Chief Executive Officer of
Vaxxinity, will participate in a fireside chat at the Bank of
America Securities 2022 Healthcare Conference, being held in Las
Vegas, Nevada on Thursday, May 12, 2022 at 10:40 a.m. PT.
A live webcast of the fireside chat can be accessed under
“Events & Presentations” in the Investor section of the
Company’s website, https://ir.vaxxinity.com/events-presentations,
and will be available for replay for 90 days following the
event.
About Vaxxinity
Vaxxinity, Inc. is a purpose-driven biotechnology company
committed to democratizing healthcare across the globe. The company
is pioneering a new class of synthetic, peptide-based
immunotherapeutic vaccines aimed at disrupting the existing
treatment paradigm for chronic disease, increasingly dominated by
monoclonal antibodies, which suffer from prohibitive costs and
cumbersome administration. The company’s proprietary technology
platform has enabled the innovation of novel pipeline candidates
designed to bring the efficiency of vaccines to the treatment of
chronic diseases, including Alzheimer’s, Parkinson’s, migraine, and
hypercholesterolemia. The technology is also implemented as part of
a COVID-19 vaccine program. Vaxxinity has optimized its pipeline to
achieve a potentially historic, global impact on human health.
For more information about Vaxxinity, Inc., visit
http://www.vaxxinity.com and follow us on social media
@vaxxinity.
Forward-looking Statement
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. The use of certain words, including “believe,” “may,”
“continue,” “advancing,” and “will” and similar expressions, are
intended to identify forward-looking statements. These
forward-looking statements involve substantial risks and
uncertainties, including statements that are based on the current
expectations and assumptions of Vaxxinity’s management about the
development of a new class of immunotherapeutic vaccines and the
innovation and efficacy of Vaxxinity’s product candidates. Various
important factors could cause actual results or events to differ
materially from those that may be expressed or implied by our
forward-looking statements. Additional important factors to be
considered in connection with forward-looking statements are
described in the “Risk Factors” section of the Company’s Annual
Report on Form 10-K filed with the Securities and Exchange
Commission on March 24, 2022. The forward-looking statements are
made as of this date and Vaxxinity does not undertake any
obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
Investor ContactClaudia Styslinger
vaxxinity@argotpartners.com
Press ContactPhilip
Cowdellmedia@vaxxinity.com
Vaxxinity (NASDAQ:VAXX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxxinity (NASDAQ:VAXX)
Historical Stock Chart
From Apr 2023 to Apr 2024